{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:42:15Z","timestamp":1784868135248,"version":"3.55.0"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck & Co., Inc. | Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:p>The World Health Organization has identified antimicrobial resistance as a global public health threat since the prevalence and spread of antibiotic resistance among bacterial pathogens worldwide are staggering. Carbapenems, such as imipenem and meropenem, have been used to treat multidrug-resistant bacteria; however, since the development of resistance to carbapenems, \u03b2-lactam antibiotics in combination with \u03b2-lactamase inhibitors (BLI) has been one of the most successful strategies to enhance the activity of \u03b2-lactam antibiotics.<\/jats:p>","DOI":"10.1128\/aac.02577-17","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T12:51:32Z","timestamp":1528203092000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":27,"title":["<i>In Vivo<\/i>\n            Efficacy of Relebactam (MK-7655) in Combination with Imipenem-Cilastatin in Murine Infection Models"],"prefix":"10.1128","volume":"62","author":[{"given":"Mary Ann","family":"Powles","sequence":"first","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Galgoci","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Misura","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Colwell","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen H.","family":"Dingley","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wu","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Blizzard","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Motyl","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Young","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Antibiotic resistance threats in the United States, 2013","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA. https:\/\/www.cdc.gov\/drugresistance\/pdf\/ar-threats-2013-508.pdf."},{"key":"e_1_3_2_3_2","volume-title":"Antimicrobial resistance: global report on surveillance, 2014","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. 2014. Antimicrobial resistance: global report on surveillance, 2014. World Health Organization, Geneva, Switzerland. http:\/\/apps.who.int\/iris\/bitstream\/10665\/112642\/1\/9789241564748_eng.pdf?ua=1."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70054-4"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.PLAS-0016-2013"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01009-09"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.009142-0"},{"key":"e_1_3_2_8_2","first-page":"218","article-title":"The impact of carbapenemases on antimicrobial development and therapy","volume":"3","author":"Livermore DM","year":"2002","unstructured":"Livermore DM. 2002. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Investig Drugs 3:218\u2013224.","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq108"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025247"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014556652"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.12.101"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02316-16"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02209-16"},{"key":"e_1_3_2_15_2","article-title":"Retrospective analysis of the effect of MK-7655 (relebactam) on imipenem non-susceptible Pseudomonas aeruginosa and KPC-expressing Enterobacteriaceae, abstr","author":"Young K","year":"2015","unstructured":"Young K, Motyl M. 2015. Retrospective analysis of the effect of MK-7655 (relebactam) on imipenem non-susceptible Pseudomonas aeruginosa and KPC-expressing Enterobacteriaceae, abstr. Intersci Conf Antimicrob Agents Chemother\/Int Cong Chemother Meet.","journal-title":"Intersci Conf Antimicrob Agents Chemother\/Int Cong Chemother Meet"},{"key":"e_1_3_2_16_2","article-title":"In vitro activity of the class A and C \u03b2-lactamase inhibitor MK-7655, abstr","author":"Young K","year":"2010","unstructured":"Young K, Raghoobar SL, Newsome NN, Painter RE, Racine F, Dorso KL, Hermes JD, Hammond ML, Motyl MR. 2010. In vitro activity of the class A and C \u03b2-lactamase inhibitor MK-7655, abstr. Intersci Conf Antimicrob Agents Chemother.","journal-title":"Intersci Conf Antimicrob Agents Chemother"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05927-11"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.922-926.2001"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00633-16"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02577-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02577-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:19:31Z","timestamp":1645478371000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02577-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1128\/AAC.02577-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.02577-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"2017-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02577-17"}}